A new protein-based nanoparticle vaccine protected mice against a variety of coronaviruses, researchers have shown.
List view / Grid view
Filter the results
The novel probes, known as positive controls, could make it easier to validate rapid, point-of-care diagnostic tests for COVID-19 across the globe.
The synthetic protein nanoparticle can cross the blood-brain barrier and deliver a targeted therapeutic to glioblastoma cells, say researchers.
Scientists have developed a new assay that uses nanoparticles to mimic how SARS-CoV-2 infects a cell, which could be used to screen for drugs that treat COVID-19.
The novel nanoparticle delivered Mp6 peptide was able to inhibit thrombosis and reduce inflammation without increasing the risk of bleeding in mice after heart attacks.
Researchers have developed 'nanosponges' cloaked in lung cell membranes and macrophage membranes which they found could attract and neutralise COVID-19 in cell cultures.
Scientists created a technique to give photoreceptors infrared-light sensitivity, allowing the animal models to see infrared heat signatures.
Multidrug nanoparticles for the targeted delivery of drugs could be used to combat inflammation in COVID-19 patients, say researchers.
Using dye-loaded nanoparticles which can heat up with near-infrared light, researchers have been able to image and treat endometriosis in animal models.
A novel 4D printer has been created which can combine organic chemistry, surface science and nanolithography to design surfaces with organic or biological molecules for drug research.
A study has shown that inexpensive nanoparticles can effectively inhibit PD-L1 in cancer cells in the lab and work as well as antibodies, providing a potential alternative immunotherapy.
A new double-layered nanoparticle vaccine protected mice against six strains of the flu and may provide the basis for the first universal vaccine against seasonal influenza, according to research.
Peptide-based nanoparticles have been designed which can suppress pancreatic cancer growth without the toxic side effects.
The SCIB2 vaccine is to to be administered using new nanoparticle formulation in planned Phase 1/2 clinical trial.